SCHEMBL8320119

SCHEMBL8320119

Fc1ccc(F)c(-c2cnc3[nH]cc(-c4ccoc4)c3c2)c1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 0.66
CCNT1 O60563 2/20 0.53
CCNA2 P20248 2/20 0.53
CDK2 P24941 2/20 0.53
CDK9 P50750 2/20 0.53
DYRK1A Q13627 4/20 0.49
CLK1 P49759 2/20 0.49
DYRK2 Q92630 2/20 0.49
DYRK1B Q9Y463 2/20 0.49
CLK2 P49760 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
KIT P10721 2/20 0.46
AXL P30530 3/20 0.46
TNIK Q9UKE5 1/20 0.46
MAP3K11 Q16584 2/20 0.46
IGF1R P08069 1/20 0.45
ALK Q9UM73 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8320470 0.90 CDK8 (0.66) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL8320981 0.88 CDK8 (0.73) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL8313393 0.88 CDK8 (0.77) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL13745265 0.85 CDK8 (0.70) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL8321131 0.85 KIT (0.61) CDK8DYRK1AKITMAP3K11
SCHEMBL8320045 0.85 CDK8 (0.73) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL8320115 0.84 CDK8 (0.84) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL13745366 0.83 CDK8 (0.77) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL8319983 0.82 CDK8 (0.65) CDK8CCNT1CCNA2CDK2CDK9
SCHEMBL8322704 0.81 CDK8 (0.66) CDK8CCNT1CCNA2CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 CDK8 360/4885CCNT1 1186/4885CCNA2 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.